CN110520141A - 用于治疗接受造血干细胞移植的患者的粪便微生物群 - Google Patents

用于治疗接受造血干细胞移植的患者的粪便微生物群 Download PDF

Info

Publication number
CN110520141A
CN110520141A CN201880008477.0A CN201880008477A CN110520141A CN 110520141 A CN110520141 A CN 110520141A CN 201880008477 A CN201880008477 A CN 201880008477A CN 110520141 A CN110520141 A CN 110520141A
Authority
CN
China
Prior art keywords
sample
fecal microbiota
csh
transplantation
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880008477.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·摩西
H·索科尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59325347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110520141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université filed Critical Assistance Publique - Hôpitaux de Paris
Publication of CN110520141A publication Critical patent/CN110520141A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880008477.0A 2017-01-26 2018-01-26 用于治疗接受造血干细胞移植的患者的粪便微生物群 Pending CN110520141A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1750629 2017-01-26
FR1750629A FR3062063B1 (fr) 2017-01-26 2017-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
PCT/EP2018/051941 WO2018138251A1 (fr) 2017-01-26 2018-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques

Publications (1)

Publication Number Publication Date
CN110520141A true CN110520141A (zh) 2019-11-29

Family

ID=59325347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880008477.0A Pending CN110520141A (zh) 2017-01-26 2018-01-26 用于治疗接受造血干细胞移植的患者的粪便微生物群

Country Status (20)

Country Link
US (1) US20200188450A1 (enExample)
EP (1) EP3573631B1 (enExample)
JP (1) JP7527109B2 (enExample)
KR (1) KR102517287B1 (enExample)
CN (1) CN110520141A (enExample)
AU (1) AU2018212530B2 (enExample)
CA (1) CA3051807C (enExample)
DK (1) DK3573631T3 (enExample)
ES (1) ES2937965T3 (enExample)
FI (1) FI3573631T3 (enExample)
FR (1) FR3062063B1 (enExample)
HR (1) HRP20230122T1 (enExample)
HU (1) HUE061155T2 (enExample)
IL (1) IL268237B (enExample)
LT (1) LT3573631T (enExample)
PL (1) PL3573631T3 (enExample)
PT (1) PT3573631T (enExample)
RS (1) RS63978B1 (enExample)
SI (1) SI3573631T1 (enExample)
WO (1) WO2018138251A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200038506A (ko) * 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
US20220023419A1 (en) * 2018-11-28 2022-01-27 The Council Of The Queensland Institute Of Medical Research Inhibiting inflammation
CN112375705A (zh) * 2020-11-12 2021-02-19 安徽燕婉健康科技有限公司 一种替代天然菌群的肠壁移植优势菌的制备方法及其应用
EP4386090A1 (en) * 2022-12-12 2024-06-19 Assistance Publique - Hôpitaux De Paris Method for determining and improving the potential efficacy of anticancer treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103561752A (zh) * 2011-03-09 2014-02-05 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US20160143961A1 (en) * 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
WO2016086161A1 (en) * 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
WO2016170285A1 (fr) * 2015-04-24 2016-10-27 Maat Pharma Procédé de préparation d'un échantillon de microbiote fécal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649719B1 (fr) * 1989-07-17 1993-08-27 Cerbio Sa Procede de protection et de conservation de micro-organismes notamment de bacteries
CN104918624A (zh) * 2012-11-26 2015-09-16 托马斯·朱利叶斯·波洛迪 恢复排泄物微生物群的组合物及其制造和使用方法
WO2016057671A1 (en) * 2014-10-07 2016-04-14 University Of Virginia Patent Foundation Compositions and methods for preventing and treating infection
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103561752A (zh) * 2011-03-09 2014-02-05 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US20160143961A1 (en) * 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
WO2016086161A1 (en) * 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
WO2016170285A1 (fr) * 2015-04-24 2016-10-27 Maat Pharma Procédé de préparation d'un échantillon de microbiote fécal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTHIAS LOEBE: "Multiple-organ transplantation from a single donor", 《TEX HEART INST J》 *

Also Published As

Publication number Publication date
KR102517287B1 (ko) 2023-03-31
PL3573631T3 (pl) 2023-05-02
RS63978B1 (sr) 2023-03-31
IL268237A (en) 2019-09-26
AU2018212530A1 (en) 2019-09-05
EP3573631A1 (fr) 2019-12-04
SI3573631T1 (sl) 2023-09-29
US20200188450A1 (en) 2020-06-18
AU2018212530B2 (en) 2022-06-23
PT3573631T (pt) 2023-01-24
ES2937965T3 (es) 2023-04-03
FR3062063B1 (fr) 2019-04-19
CA3051807A1 (fr) 2018-08-02
FI3573631T3 (fi) 2023-03-02
JP7527109B2 (ja) 2024-08-02
KR20190130563A (ko) 2019-11-22
FR3062063A1 (fr) 2018-07-27
HUE061155T2 (hu) 2023-05-28
JP2020506183A (ja) 2020-02-27
WO2018138251A1 (fr) 2018-08-02
HRP20230122T1 (hr) 2023-03-31
CA3051807C (fr) 2023-07-11
IL268237B (en) 2022-07-01
EP3573631B1 (fr) 2022-11-16
LT3573631T (lt) 2023-03-10
DK3573631T3 (da) 2023-01-30

Similar Documents

Publication Publication Date Title
CN107530280B (zh) 粪便微生物群样品的制备方法
KR102341203B1 (ko) 분변 미생물총의 샘플의 동결건조 방법
ES3010296T3 (en) Intestinal microbiota and gvhd
AU2012229902B2 (en) Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response
JP7527109B2 (ja) 造血幹細胞移植を受けている患者を治療するための便細菌叢
CN112805367A (zh) 用于治疗艰难梭菌的方法和组合物
US20200038459A1 (en) Composition comprising fecal microbiota
JP2019521089A (ja) 乳酸菌由来のｐ８蛋白質及びその抗癌剤としての使用
NL8101452A (nl) Werkwijze voor het bereiden van een preparaat ter behandeling van tumoren.
Quiroga et al. Infective endocarditis on a percoutaneous prosthetic aortic valve with associated glomerulopathy due to Granulicatella adjacens
EP1881838B1 (en) Antitumor agent on the base of bcg vaccine, method for its preparation and its use
KR20210040395A (ko) 이식편 대 숙주 질환의 치료를 위한 조성물
Lehn et al. Bone marrow transplantation for chronic granulocytic leukemia
Sung et al. Double high-dose chemotherapy with autologous stem cell transplantation in patients with high-risk neuroblastoma: a pilot study in a single center
CN121014615A (zh) 一种经血保存液及经血来源间充质干细胞冻存方法
CN121128709A (zh) 一种脐带间充质干细胞制剂保存液及其制备方法
CN120330098A (zh) 一种抗衰老复合益生菌及其应用
Miller et al. Use of tumor lines with selectable markers in assessing the effect on experimental metastases of combination chemotherapy with alkylating agents
Storb Treatment of Acute Leukemia in Remission by Bone Marrow Transplantation
Hillyer T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation: WR Drobyski, MJ Hessner, JP Klein, et al. Blood 94: 434–441, 1999
Litzow 15 Blood and Marrow Transplantation
Kebriaei et al. Inferior Outcome With Addition Of Rituximab For Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Acute Lymphoblastic Leukemia (ALL)
Houbiers et al. Blood Transfusion and Cancer: Modulation or Tolerance?
NZ197018A (en) Propionibacterium preparation(injectable)tumour treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191129

RJ01 Rejection of invention patent application after publication